Immune System Key Ltd.
  • Home
  • News & Events
  • Science And R&D
    • Nerofe Pipeline
    • Technology
    • Nerofe Mode of Action
    • Phase I Results
    • First Success Story
  • Company Description
    • Team
  • Contact Us
Immune System Key Ltd.
  • Home
  • News & Events
  • Science And R&D
    • Nerofe Pipeline
    • Technology
    • Nerofe Mode of Action
    • Phase I Results
    • First Success Story
  • Company Description
    • Team
  • Contact Us

ISK received the FDA’s approval to start Phase 1b/2a with AML patients

  • Home
  • News
  • ISK received the FDA’s approval to start Phase 1b/2a with AML patients

ISK received the FDA’s approval to start Phase 1b/2a with AML patients

January 9, 2020
Joel Ohana2020-01-15T14:27:25+00:0009 Jan|

Related Posts

  • PHASE 1B/2A Clinical trial started

    April 13, 2021

  • Cooperation with Harvard Medical School (MGH)

    October 27, 2019

    ISK has signed an agreement for cooperation with Harvard Medical School for drug development to treat neurodegenerative diseases
  • Usylvester
    Permalink Gallery

    PHASE 1B/2A Clinical trial started

  • Permalink Gallery

    Cooperation with Harvard Medical School (MGH)

Recent Posts

  • Harvard medical school and ISK Ltd submitted a grant application for a clinical trial with Alzheimer’s patients
  • PHASE 1B/2A Clinical trial started
  • ISK received the FDA’s approval to start Phase 1b/2a with AML patients
  • Cooperation with Harvard Medical School (MGH)

Tags

Alzheimer's disease AML cancer Clinical Trial ISK MDS Nerofe Phase 1 Treatment

Categories

  • News
  • About
  • News & Events
  • Contact Us
  • Disclaimer
Immune System Key (ISK) Ltd. Hava'ad Haleumi 21, Jerusalem 91160, Israel Tel: +972-50-2597031/2
logo
Copyright © 2015 ISK Ltd.